

Dialogues in Contraception[®], Volume 11, Issue 1 References

Please click on the Reference Section below to go directly to that section's reference list. You can also scroll from this page to view all of the references.

Reference Sections

[Depot Medroxyprogesterone Acetate and Bone Density](#)

[Polycystic Ovary Syndrome: Management and Contraception](#)

[Emergency Contraception: An Update](#)

Depot Medroxyprogesterone Acetate and Bone Density

1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. *Adv Data*. 2004;350:1-35.
2. Abma JC, Martinez GM, Mosher WD, Dawson BS. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002. National Center for Health Statistics. *Vital Health Stat*. 2004;23:i-79.
3. Cromer B. In favor of continued use of depot medroxyprogesterone acetate (DMPA, Depo-Provera) in adolescents. *J Pediatr Adolesc Gynecol*. 2005;18:183-188.
4. Santelli JS, Morrow B, Anderson JE, Lindberg LD. Contraceptive use and pregnancy risk among U.S. high school students, 1991-2003. *Perspect Sex Reprod Health*. 2006;38:106-111.
5. Santelli JS, Abma J, Ventura S, et al. Can changes in sexual behaviors among high school students explain the decline in teen pregnancy rates in the 1990s? *J Adolesc Health*. 2004;35:80-90.
6. Depo-Provera[®] [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn Company; 2004.
7. Depo-subQ provera 104[™] [package insert]. New York, NY: Pharmacia & Upjohn Co., Division of Pfizer Inc; 2005.
8. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. *J Reprod Med*. 1996;41:381-390.
9. Speroff L, Darney PD. Injectable contraception. In: *A Clinical Guide for Contraception*. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: chap 6.
10. Clark MK, Sowers M, Levy BT, Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. *Fertil Steril*. 2001;75:871-877.
11. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. *Contraception*. 2004;70:269-275.
12. Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. *Ann Oncol*. 2002;13:883-888.
13. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. *N Engl J Med*. 1994;331:347-352.



14. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM. Depot medroxyprogesterone acetate and bone mineral density in adolescents—the black box warning: a position paper of the Society for Adolescent Medicine. *J Adolesc Health*. 2006;39:296-301.
15. Shaarawy M, El-Mallah SY, Seoudi S, Hassan M, Mohsen IA. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. *Contraception*. 2006;74:297-302.
16. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. *Arch Pediatr Adolesc Med*. 2005;159:139-144.
17. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. *Epidemiology*. 2002;13:581-587.
18. Rome E, Ziegler J, Secic M, et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. *J Pediatr Adolesc Gynecol*. 2004;17:373-377.
19. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. *J Pediatr Adolesc Gynecol*. 2004;17:17-21.
20. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. *Obstet Gynecol*. 2004;103:899-906.
21. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. *Contraception*. 2006;73:470-487.
22. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. *Br Med J*. 1991;303:13-16.
23. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. *Obstet Gynecol*. 1998;92:569-573.
24. Cundy T, Cornish J, Roberts H, Reid IR. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. *Am J Obstet Gynecol*. 2002;186:978-983.
25. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. *J Adolesc Health*. 2004;35:434-441.



26. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. *J Pediatr*. 1996;129:671-676.
27. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. *Fertil Steril*. 2004;82:1580-1586.
28. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. *Fertil Steril*. 2006;86:1466-1474.
29. Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesterone acetate. *Contraception*. 2006;73:577-583.
30. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. *Obstet Gynecol*. 1999;93:233-238.
31. Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O, for the WHO Study of Hormonal Contraception and Bone Health. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. *Obstet Gynecol*. 2000;95:736-744.
32. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. *Contraception*. 2006;74:90-99.
33. Scholes D, Lacroix AZ, Ichikawa LE, Barlow WE, Ott SM. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. *Contraception*. 2004;69:99-104.
34. Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. *Contraception*. 1997;56:1-3.
35. Perrotti M, Bahamondes L, Petta C, Castro S. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. *Fertil Steril*. 2001;76:469-473.
36. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. *Hum Reprod*. 2006;21:248-256.



37. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. *Fertil Steril*. 2006;85:314-325.
38. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. *BMJ*. 1994;308:247-248.
39. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. *Clin Endocrinol (Oxf)*. 1998;49:615-618.
40. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. *J Clin Endocrinol Metab*. 1992;75:1060-1065.
41. Bonny AE, Harkness LS, Cromer BA. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female. *Adolesc Med*. 2005;16:569-584.
42. Holmberg-Marttila D, Sievänen H, Laippala P, Tuimala R. Factors underlying changes in bone mineral during postpartum amenorrhea and lactation. *Osteoporos Int*. 2000;11:570-576.
43. Karlsson C, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. *Osteoporos Int*. 2001;12:828-834.
44. Kalkwarf HJ, Specker BL, Bianchi DC, Ranz J, Ho M. The effect of calcium supplementation on bone density during lactation and after weaning. *N Engl J Med*. 1997;337:523-528.
45. Polatti F, Capuzzo E, Viazzo F, Colleoni R, Klersy C. Bone mineral changes during and after lactation. *Obstet Gynecol*. 1999;94:52-56.
46. Laskey MA, Prentice A, Hanratty LA, et al. Bone changes after 3 mo of lactation: influence of calcium intake, breast-milk output, and vitamin D-receptor genotype. *Am J Clin Nutr*. 1998;67:685-692.
47. Kalkwarf HJ, Specker BL. Bone mineral loss during lactation and recovery after weaning. *Obstet Gynecol*. 1995;86:26-32.
48. Chantry CJ, Auinger P, Byrd RS. Lactation among adolescent mothers and subsequent bone mineral density. *Arch Pediatr Adolesc Med*. 2004;158:650-656.
49. Kaunitz AM. Depo-Provera's black box: time to reconsider? *Contraception*. 2005;72:165-167.



50. US Food and Drug Administration. Black box warning added concerning long-term use of Depo-Provera Contraceptive Injection. Available at: <http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html>. Accessed December 30, 2004.
51. American College of Obstetricians and Gynecologists. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. *Obstet Gynecol.* 2006;107:1453-1472.
52. World Health Organization. WHO Statement on hormonal contraception and bone health. Available at: http://www.who.int/reproductive-health/family_planning/bone_health.html. Accessed January 30, 2007.
53. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. Technical Report Series, No. 843; 1994. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_843.pdf. Accessed September 8, 2006.
54. Kanis JA, for the Committee of Scientific Advisors IOF. An update on the diagnosis and assessment of osteoporosis with densitometry. *Osteoporos Int.* 2000;11:192-202.
55. McClung MR. The relationship between bone mineral density and fracture risk. *Curr Osteopor Rep.* 2005;3:57-63.
56. Leslie WD, Adler RA, Fuleihan GE, et al. Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. *J Clin Densitom.* 2006;9:22-30.
57. Fosamax [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2006.
58. Actonel[®] [package insert]. Cincinnati, Ohio: Procter & Gamble Pharmaceuticals, Inc.; 2006.
59. Evista[®] [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2003.
60. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. *J Clin Oncol.* 1996;14:78-84.
61. Forteo[®] [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2004.
62. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Available at: <http://www.nap.edu/catalog/5776.html>. Accessed March 14, 2007.



63. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. *Br J Obstet Gynaecol.* 1998;105:790-794.
64. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. *Am J Obstet Gynecol.* 1996;175:396-401.

Polycystic Ovary Syndrome: Management and Contraception

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab.* 2004;89:2745-2749.
2. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Healthcare-related economic burden of the polycystic ovary syndrome (PCOS) during the reproductive lifespan. *J Clin Endocrinol Metab.* 2005;90:4650-4658.
3. Speroff L, Fritz MA. Anovulation and the polycystic ovary. In: *Clinical Gynecologic Endocrinology and Infertility.* 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:1013-1067.
4. Guzick DS. Polycystic ovary syndrome. *Obstet Gynecol.* 2004;103:181-193.
5. Kahn JA, Gordon CM. Polycystic ovary syndrome. *Adolesc Med.* 1999;10:321-336.
6. Elting MW, Korsen TJM, Schoemaker J. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome. *Clin Endocrinol (Oxf).* 2001;55:767-776.
7. American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetrician-gynecologists. ACOG Practice Bulletin number 41. *Obstet Gynecol.* 2002;100:1389-1402.
8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocr Rev.* 1997;18:774-800.
9. Azziz R, Carmina E, Dewailly D, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab.* 2006;91:4237-4245.
10. Murphy MK, Hall JE, Adams JM, Lee H, Welt CK. Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2006;91:3878-3884.



11. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. *J Clin Endocrinol Metab.* 2006;91:3922-3927.
12. Mueller A, Dittrich R, Binder H, Hoffmann I, Beckmann MW, Cupisti S. Endocrinological markers for assessing hyperandrogenemia in women classified as having polycystic ovary syndrome (PCOS) according to the revised 2003 diagnostic criteria. *Eur J Med Res.* 2006;11:540-544.
13. Broekmans FJ, Knauff EAH, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. *BJOG.* 2006;113:1210-1217.
14. Stenchever M, Droegemueller W, Herbst AL, Mishell DR Jr. Reproductive endocrinology and infertility. In: *Comprehensive Gynecology.* 4th ed. St. Louis, Mo: Mosby Inc.; 1219-1220.
15. Lazarou S, Reyes-Vallejo L, Morgentaler A. Wide variability in laboratory reference values for serum testosterone. *J Sex Med.* 2006;3:1085-1089.
16. Palaniappan LP, Carnethon MR, Fortmann SP. Heterogeneity in the relationship between ethnicity, BMI, and fasting insulin. *Diabetes Care.* 2002;25:1351-1357.
17. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. *Obstet Gynecol Surv.* 2004;59:141-154.
18. Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. *Arterioscler Thromb Vasc Biol.* 1995;15:821-826.
19. McLaughlin T, Abbasi F, Kim HS, Lamendola C, Schaaf P, Reaven G. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. *Metabolism.* 2001;50:795-800.
20. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. *Fertil Steril.* 2005;83:1454-1460.
21. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. *Hum Reprod.* 2000;15:1266-1274.
22. Kidson W. Polycystic ovary syndrome: a new direction in treatment. *Med J Aust.* 1998;169:537-540.
23. Legro RS. Polycystic ovary syndrome: long term sequelae and management. *Minerva Ginecol.* 2002;54:97-114.



24. Crosignani PG. Hormones and cardiovascular health in women. *Hum Reprod Update*. 2006;12:483-497.
25. Apridonidze T, Essah PA, Luorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2005;90:1929-1935.
26. Dahlgren E, Friberg LG, Johansson S, et al. Endometrial carcinoma; ovarian dysfunction—a risk factor in young women. *Eur J Obstet Gynecol Reprod Biol*. 1991;41:143-150.
27. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. *Obstet Gynecol*. 1983;61:403-407.
28. Escobedo LG, Lee NC, Peterson HB, Wingo PA. Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. *Obstet Gynecol*. 1991;77:124-128.
29. Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. *Hum Reprod Update*. 2006;12:673-683.
30. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. *Hum Reprod*. 2002;17:2858-2864.
31. Amer SAK, Gopalan V, Li TC, Ledger WL, Cooke ID. Long term follow-up of patients with polycystic ovarian syndrome after laparoscopic ovarian drilling: clinical outcome. *Hum Reprod*. 2002;17:2035-2042.
32. Jakubowicz DJ, Luorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2002;87:524-529.
33. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. *Metabolism*. 1999;48:1589-1595.
34. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. *Hum Reprod*. 2001;16:2606-2609.
35. Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. *Hum Reprod*. 1995;10:2705-2712.



36. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. *Fertil Steril*. 1994;61:598-604.
37. Huber-Buchholz MM, Carey DGP, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. *J Clin Endocrinol Metab*. 1999;84:1470-1474.
38. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. *Hum Reprod*. 1998;13:1502-1505.
39. Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. *Hum Reprod*. 1996;11:1884-1891.
40. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. *J Clin Endocrinol Metab*. 2003;88:148-156.
41. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2000;85:2767-2774.
42. Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. *Gynecol Endocrinol*. 2002;16:217-224.
43. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. *Hum Reprod*. 2006;21:1400-1407.
44. Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. *Fertil Steril*. 2006;85:428-435.
45. Lanham MSM, Lebovic DI, Domino SE. Contemporary medical therapy for polycystic ovary syndrome. *Int J Gynaecol Obstet*. 2006;95:236-241.
46. Moll E, Bossuyt PMM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. *Br Med J*. 2006;332:1485.



47. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. *N Engl J Med.* 2007;356:551-566.
48. Khorram O, Helliwell JP, Katz S, Bonpane CM, Jaramillo L. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. *Fertil Steril.* 2006;85:1448-1451.
49. Farquhar C, Vandekerckhove P, Lilford R. Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome (Cochrane Review). In: *The Cochrane Library*, Issue 3, Oxford: Update software.
50. Diamanti-Kandarakis E, Baillargeon JP, Luorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. *J Clin Endocrinol Metab.* 2003;88:1927-1932.
51. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. *Hum Reprod.* 2006;22:317-322.
52. Gaspard UJ, Lefebvre PJ. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. *Am J Obstet Gynecol.* 1990;163:334-343.
53. Gaspard U, Scheen A, Endrikat J, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. *Contraception.* 2003;67:423-429.
54. Cibula D, Fanta M, Sindelka G, Hill M, Skrha J, Zivny J. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. *Hum Reprod.* 2002;17:76-82.
55. Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. *Clin Endocrinol (Oxf).* 1999;50:517-527.
56. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. *Hum Reprod.* 2002;17:1729-1737.
57. Kjos SL, Shoupe D, Douyan S, et al. Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study. *Am J Obstet Gynecol.* 1990;163:1822-1827.
58. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. *JAMA.* 1998;280:533-538.



59. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. *JAMA*. 1994;271:1099-1102.
60. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. *World Health Organ Tech Rep Ser*. 1998;877:i-89.
61. Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. *Arch Intern Med*. 2001;161:1065-1070.
62. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. *N Engl J Med*. 1996;335:8-15.
63. Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. *Circulation*. 1998;98:1058-1063.
64. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. *Stroke*. 1998;29:2277-2284.
65. Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, Quesenberry CP, Jr. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. *Contraception*. 2004;70:3-10.
66. World Health Organization. *Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use*. 3rd ed. Geneva, Switzerland: World Health Organization; 2004.
67. Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. *Obstet Gynecol*. 2002;99:820-827.
68. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system: the analysis of pooled data. *Fertil Steril*. 2002;77(suppl 2):S13-S18.
69. Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. *Obstet Gynecol*. 2005;105:46-52.
70. Brunner Huber LR, Hogue CJ, Stein AD, Drews C, Zieman M. Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. *Ann Epidemiol*. 2006;16:637-643.
71. Brunner Huber LR, Hogue CJ. The association between body weight, unintended pregnancy resulting in a livebirth, and contraception at the time of conception. *Matern Child Health J*. 2005;9:413-420.



72. Zhang HF, LaGuardia KD, Creanga DL. Higher body weight and body mass index are not associated with reduced efficacy in Ortho Tri-Cyclen Lo users [abstract]. *Obstet Gynecol.* 2006;107:50S.
73. Westhoff C. Higher body weight does not affect NuvaRing[®]'s efficacy. Poster presented at: American College of Obstetricians and Gynecologists 52nd Annual Clinical Meeting; May 1-5, 2005; Philadelphia, Pa.
74. Westhoff CL, Anderson FD. Seasonale (30 µg of ethinyl estradiol/150 µg of levonorgestrel) extended-regimen oral contraceptive: efficacy and cycle control by body weight [abstract]. *Contraception.* 2006;74:181-182. Abstract 13.
75. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. *Am J Obstet Gynecol.* 2005;192:2055-2059.
76. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. *Contraception.* 2006;73:23-29.
77. Lemay A, Poulin Y. Oral contraceptives as anti-androgenic treatment of acne. *J Obstet Gynaecol Can.* 2002;24:559-567.
78. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. *J Natl Cancer Inst.* 1996;88:1127-1135.
79. Cancer and Steroid Hormone Study of the Centers for Disease Control, National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. *JAMA.* 1987;257:796-800.
80. Rosenblatt KA, Thomas DB, and the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. *Int J Cancer.* 1991;49:870-874.
81. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner's guide to meta-analysis. *Hum Reprod.* 1997;12:1851-1863.
82. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. *Obstet Gynecol.* 1993;82:931-935.
83. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). *Cancer Causes Control.* 1999;10:277-284.
84. Stanford JL, Brinton LA, Berman ML, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? *Int J Cancer.* 1993;54:243-248.



85. Davis A, Godwin A, Lippman J, Olson W, Kafrisen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. *Obstet Gynecol.* 2000;96:913-920.

Emergency Contraception: An Update

1. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists, Number 69, December 2005 (replaces Practice Bulletin Number 25, March 2001). Emergency contraception. *Obstet Gynecol.* 2005;106:1443-1452.
2. US Food and Drug Administration. FDA approves over-the-counter access for Plan B for women 18 and older prescription remains required for those 17 and under. Available at: <http://www.fda.gov/bbs/topics/NEWS/2006/NEW01436.html>. Accessed January 24, 2007.
3. Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. *Lancet.* 1998;352:428-433.
4. Ellertson C, Trussell J, Stewart F, Koenig J, Raymond EG, Shochet T. Emergency contraception. *Semin Reprod Med.* 2001;19:323-330.
5. Plan B [package insert]. Pomona, NY: Duramed Pharmaceuticals, Inc.; 2006.
6. Raymond E, Taylor D, Trussell J, Steiner MJ. Minimum effectiveness of the levonorgestrel regimen of emergency contraception. *Contraception.* 2004;69:79-81.
7. Stewart F, Trussell J, Van Look PFA. Emergency contraception. In: *Contraceptive Technology*. 18th ed. New York, NY: Ardent Media Inc.; 2004.
8. Trussell J, Ellertson C. Efficacy of emergency contraception [review]. *Fert Control Rev.* 1995;4:8-11.
9. Raymond EG, Trussell J, Polis CB. Population effect of increased access to emergency contraceptive pills: a systematic review. *Obstet Gynecol.* 2007;109:181-188.
10. Raine TR, Harper CC, Rocca CH, et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. *JAMA.* 2005;293:54-62.
11. Harper CC, Cheong M, Rocca CH, Darney PD, Raine TR. The effect of increased access to emergency contraception among young adolescents. *Obstet Gynecol.* 2005;106:483-491.



12. Walsh TL, Frezieres RG. Patterns of emergency contraception use by age and ethnicity from a randomized trial comparing advance provision and information only. *Contraception*. 2006;74:110-117.
13. Glasier A, Fairhurst K, Wyke S, et al. Advanced provision of emergency contraception does not reduce abortion rates. *Contraception*. 2004;69:361-366.
14. Glasier A, Baird D. The effects of self-administering emergency contraception. *N Engl J Med*. 1998;339:1-4.
15. Soon JA, Levine M, Osmond BL, Ensom MHH, Fielding DW. Effects of making emergency contraception available without a physician's prescription: a population-based study. *CMAJ*. 2005;172:878-883.
16. Jackson RA, Schwarz EB, Freedman L, Darney P. Advance supply of emergency contraception: effect on use and usual contraception-a randomized trial. *Obstet Gynecol*. 2003;102:8-16.
17. Belzer M, Sanchez K, Olson J, Jacobs AM, Tucker D. Advance supply of emergency contraception: a randomized trial in adolescent mothers. *J Pediatr Adolesc Gynecol*. 2005;18:347-354.
18. Gold MA, Wolford JE, Smith KA, Parker AM. The effects of advance provision of emergency contraception on adolescent women's sexual and contraceptive behaviors. *J Pediatr Adolesc Gynecol*. 2004;17:87-96.
19. Ellertson C, Ambardekar S, Hedley A, Coyaji K, Trussell J, Blanchard K. Emergency contraception: randomized comparison of advance provision and information only. *Obstet Gynecol*. 2001;98:570-575.
20. Durand M, del Carmen Cravioto M, Raymond EG, et al. On the mechanisms of action of short-term levonorgestrel administration in emergency contraception. *Contraception*. 2001;64:227-234.
21. Marions L, Hultenby K, Lindell I, Sun X, Ståbi B, Danielsson KG. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. *Obstet Gynecol*. 2002;100:65-71.
22. Croxatto HB, Brache V, Pavez M, et al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. *Contraception*. 2004;70:442-450.
23. Gemzell-Danielsson K. Effects of levonorgestrel on ovarian function when used for emergency contraception. *Minerva Ginecol*. 2006;58:205-207.
24. Gemzell-Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. *Hum Reprod Update*. 2004;10:341-348.



25. Durand M, Seppala M, del Carmen Cravioto M, et al. Late follicular phase administration of levonorgestrel as an emergency contraceptive changes the secretory pattern of glycodeilin in serum and endometrium during the luteal phase of the menstrual cycle. *Contraception*. 2005;71:451-457.
26. Novikova N, Weisberg E, Stanczyk FZ, Croxatto HB, Fraser IS. Effectiveness of levonorgestrel emergency contraception given before or after ovulation—a pilot study. *Contraception*. 2007;75:112-118.
27. Trussell J, Jordan B. Mechanism of action of emergency contraceptive pills. *Contraception*. 2006;74:87-89.
28. von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. *Lancet*. 2002;360:1803-1810.
29. Arowojolu AO, Okewole IA, Adekunle AO. Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. *Contraception*. 2002;66:269-273.
30. Raymond EG, Goldberg A, Trussell J, Hays M, Roach E, Taylor D. Bleeding patterns after use of levonorgestrel emergency contraceptive pills. *Contraception*. 2006;73:376-381.
31. World Health Organization. *Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use*. 3rd ed. Geneva, Switzerland: World Health Organization; 2004.
32. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. *Perspect Sex Reprod Health*. 2006;38:90-96.

